ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 312 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $863 | +145.2% | 32,127 | +131.8% | 0.01% | +166.7% |
| Q1 2023 | $352 | -74.0% | 13,860 | -58.5% | 0.00% | -85.0% |
| Q4 2022 | $1,353 | -99.9% | 33,365 | -51.8% | 0.02% | -33.3% |
| Q3 2022 | $2,290,000 | +37.8% | 69,291 | +46.8% | 0.03% | +50.0% |
| Q2 2022 | $1,662,000 | +448.5% | 47,193 | +617.4% | 0.02% | +400.0% |
| Q1 2022 | $303,000 | -92.2% | 6,578 | -88.8% | 0.00% | -90.0% |
| Q4 2021 | $3,883,000 | +284.5% | 58,567 | +262.1% | 0.04% | +185.7% |
| Q3 2021 | $1,010,000 | +7.6% | 16,174 | +42.7% | 0.01% | +40.0% |
| Q2 2021 | $939,000 | +107.7% | 11,332 | +66.2% | 0.01% | +42.9% |
| Q1 2021 | $452,000 | -45.5% | 6,817 | -36.9% | 0.01% | -12.5% |
| Q4 2020 | $829,000 | +103.2% | 10,807 | -23.9% | 0.01% | -63.6% |
| Q1 2020 | $408,000 | -70.4% | 14,197 | -34.6% | 0.02% | -15.4% |
| Q4 2019 | $1,377,000 | – | 21,716 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 908,474 | $24,410,696 | 22.12% |
| Western Financial Corp/CA | 820,239 | $22,039,822 | 16.16% |
| JOHNSON & JOHNSON | 247,598 | $6,652,958 | 2.45% |
| WEALTH EFFECTS LLC | 164,750 | $4,426,835 | 2.19% |
| M28 Capital Management LP | 67,400 | $1,811,038 | 2.08% |
| Privium Fund Management B.V. | 259,036 | $6,960,298 | 2.07% |
| Evolutionary Tree Capital Management, LLC | 51,266 | $1,377,517 | 1.78% |
| Avidity Partners Management LP | 1,063,897 | $28,586,912 | 1.15% |
| SECTORAL ASSET MANAGEMENT INC | 157,552 | $4,233,422 | 0.82% |
| Vivo Capital, LLC | 137,411 | $3,692,234 | 0.40% |